Analyzing cerebrospinal fluid in patients with delirium
MOLECULAR BIOMARKERS IN DELIRIUM AND DEMENTIA
Oslo University Hospital · NCT05060614
This study is trying to find out if certain markers in the spinal fluid of people with delirium, especially those who have had hip fractures, can help us understand how delirium is connected to dementia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 700 (estimated) |
| Sex | All |
| Sponsor | Oslo University Hospital (other) |
| Locations | 1 site (Oslo, Other) |
| Trial ID | NCT05060614 on ClinicalTrials.gov |
What this trial studies
This project aims to measure biomarkers in cerebrospinal fluid (CSF) and serum samples from patients experiencing delirium, particularly those with acute hip fractures. By investigating these biomarkers, the study seeks to uncover insights into the pathophysiology of delirium and its potential connections to dementia. The research focuses on understanding the molecular mechanisms that may link these two conditions, which share clinical and epidemiological features. The findings could enhance our knowledge of delirium and its implications for dementia progression.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with acute hip fractures who are experiencing delirium.
Not a fit: Patients who are moribund or unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of delirium, potentially reducing its impact on dementia progression.
How similar studies have performed: While the exploration of biomarkers in delirium is an emerging field, similar studies have shown promise in understanding the connections between acute cognitive disturbances and neurodegenerative conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with acute hip fracture Exclusion Criteria: * Moribund patients. * Lack of consent
Where this trial is running
Oslo, Other
- Leiv Otto Watne — Oslo, Other, Norway (RECRUITING)
Study contacts
- Principal investigator: Leiv O Watne, PhD — Oslo University Hospital
- Study coordinator: Leiv O Watne, PhD
- Email: l.o.watne@gmail.com
- Phone: 40203712
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Delirium